Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab open-label extension in CAPS
2011-005154-57Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in cryopyrin-associated periodic syndrome (CAPS), sponsored by Novartis. Started Dec 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on 2011-005154-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005154-57.